IP Receptor Antibody (B-3): sc-365268

IP Receptor Antibody (B-3) is a mouse monoclonal IgG2b antibody that detects IP Receptor in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IP Receptor plays a crucial role in mediating the effects of prostacyclin (PGI2), a key prostanoid synthesized primarily in vascular tissues, which is essential for regulating vascular tone and inhibiting platelet aggregation. IP Receptor is predominantly located in vascular tissues, including the aorta, lung, and heart, where IP Receptor facilitates vasodilation and cytoprotection, thereby contributing to cardiovascular health. IP Receptor′s location is underscored by involvement in various physiological processes, including the modulation of blood pressure and the prevention of thrombosis. The gene encoding human IP Receptor is situated on chromosome 19, and IP Receptor is expressed as a glycosylated and phosphorylated protein, which enhances functional capacity and interaction with prostacyclin. By utilizing anti-IP Receptor antibody (B-3), researchers can gain valuable insights into the signaling pathways influenced by prostacyclin and implications in cardiovascular diseases, making anti-IP Receptor antibody (B-3) an indispensable tool for studies in vascular biology and pharmacology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IP Receptor Antibody (B-3) References:

1. Prostacyclin IP receptor up-regulates the early expression of C/EBPbeta and C/EBPdelta in preadipose cells.  |  Aubert, J., et al. 2000. Mol Cell Endocrinol. 160: 149-56. PMID: 10715548
2. The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor.  |  Lawler, OA., et al. 2001. Br J Pharmacol. 132: 1639-49. PMID: 11309234
3. IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues.  |  Falcetti, E., et al. 2007. Biochem Biophys Res Commun. 360: 821-7. PMID: 17624303
4. IP receptor agonist-induced DNA synthesis and proliferation in primary cultures of adult rat hepatocytes: the involvement of endogenous transforming growth factor-alpha.  |  Kimura, M., et al. 2009. J Pharmacol Sci. 109: 618-29. PMID: 19346670
5. Neuroprotective properties of prostaglandin I2 IP receptor in focal cerebral ischemia.  |  Saleem, S., et al. 2010. Neuroscience. 170: 317-23. PMID: 20621166
6. Rapakinin, Arg-Ile-Tyr, derived from rapeseed napin, shows anti-opioid activity via the prostaglandin IP receptor followed by the cholecystokinin CCK(2) receptor in mice.  |  Yamada, Y., et al. 2011. Peptides. 32: 281-5. PMID: 21129424
7. Genetic Deletion of Prostacyclin IP Receptor Exacerbates Transient Global Cerebral Ischemia in Aging Mice.  |  Shakil, H. and Saleem, S. 2013. Brain Sci. 3: 1095-108. PMID: 24634780
8. Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice.  |  Shakil, H. and Saleem, S. 2014. J Neurol Disord. 2: PMID: 25584359
9. IP-receptor and PPARs trigger the conversion of human white to brite adipocyte induced by carbaprostacyclin.  |  Ghandour, RA., et al. 2016. Biochim Biophys Acta. 1861: 285-93. PMID: 26775637
10. Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study.  |  Bravo-Marqués, R., et al. 2024. Clin Ther. 46: 509-514. PMID: 38762398

The preferred IP Receptor antibody is IP Receptor Antibody (B-6): sc-515139.